FemTech Startup Ecosystem in the United Kingdom
The UK FemTech sector went from a handful of period-tracking apps to a £1.3 billion industry in under a decade, and it now sits second only to the US in global investment. That's the headline. What follows is the map: how big the market actually is depending on who's counting, which companies made it real, and where the money still refuses to go despite the demand clearly being there.
Before any of that, a quick note on terms. Ida Tin, co-founder of the period-tracking app Clue, coined "femtech" in 2016, and the label now covers everything from ovulation apps to breast diagnostics to hormone tests you do in your bathroom. That breadth is exactly why two reports on "the same market" can disagree by a factor of four. FemTech Analytics breaks the sector into sub-markets by revenue share: pregnancy and nursing lead at 21%, reproductive health and contraception sit at 17%, menstrual health and general healthcare each hold 14%, pelvic and uterine health takes 10%, sexual health 9%, wellness 7%, menopause just 6%, and longevity and mental health trail at 2% apiece. Keep that menopause number in your back pocket. It's going to come up again, because the gap between 6% of market share and roughly 100% of British dinner-table conversation about hot flashes is one of the stranger mismatches in this whole industry.
The UK's position in the global and European FemTech landscape
Grand View Research puts the global FemTech market at $39.29 billion in 2024, heading toward $97.25 billion by 2030 at a compound annual growth rate of 16.37%. I'm anchoring to that framework throughout this piece rather than switching between it and smaller estimates floating around elsewhere, because mixing scopes is how you end up "proving" two contradictory things with the same word.
Within that global figure, the UK holds about 3.8% as of 2023. That sounds modest until you zoom into Europe, where the UK is the largest single FemTech market on the continent and home to roughly 32% of European FemTech startups. Of the 540 active FemTech startups counted across Europe in 2023, 31.8% were British. One in three European FemTech founders, roughly speaking, is building from a UK postcode.
Globally, the UK ranks second in FemTech investment, trailing only the US. That's not a participation trophy. It means the UK is one of two real gravitational centers in this industry, pulling in international capital and talent the way London's fintech scene did a decade earlier. Worth sitting with: a sector barely a decade old has already produced a clear two-horse race, and Britain is one of the horses.
How quickly the UK market has grown and where it is heading
UK FemTech revenue was $1,287.2 million in 2023, climbed to roughly $1,500 million in 2024, and Grand View Research projects it reaching $3,785.3 million by 2030, at a 16.7% compound annual growth rate from 2024 onward. That's basically the same pace as the US market, which tells you the UK isn't some slower-moving cousin trying to catch up; it's growing in step.
The Data City frames the same sector differently: current turnover of £1.3 billion, cumulative investment of £423.2 million, and annual growth of 29.1%, with turnover potentially hitting £1.4 billion by 2027. Some assessments put annual growth even closer to 30%. Different methodology, same broad story: this thing is compounding fast.
But here's a question worth sitting with rather than skating past: is 30% annual growth proof that real clinical need is finally being met, or proof that investors have found a category they like the sound of? The sub-sector data gives a partial answer. Pregnancy and nursing products dominate the revenue split while menopause care sits at just 6%, and mental health barely registers at 2%. If demand were driving growth evenly across the female lifecycle, you'd expect the money to follow women through menopause and mental health struggles the same way it follows them through pregnancy. It mostly doesn't, yet. Growth is real; coverage of the lifecycle is not.
The structure of the UK startup population: how many companies, at what stages
Ask "how many FemTech startups does the UK have" and you'll get a different answer depending on who you ask. Beauhurst counts 106 active companies using a narrower classification. Tracxn counts 301 as of May 2026, using a wider net. I'll lean on Beauhurst's figure for the structural analysis here, since it tracks funding stage in more detail, but the gap between 106 and 301 is itself a useful reminder: this sector's boundaries are still being drawn in real time.
What's not in dispute is the growth rate. Beauhurst records an 864% increase in active FemTech companies over the past decade, the highest growth rate of any sector it tracks. Translate that into plain English: ten years ago, this industry basically didn't exist in any meaningful commercial sense in Britain. Now it produces about 23 new companies a year on average.
The stage breakdown is where things get interesting, and a little sobering. Roughly 36.8% of funded startups sit at pre-seed or seed stage, and 43.8% haven't raised any external funding at all. Only 25 companies have made it to Series A or beyond. And exactly one, Flo Health, has reached unicorn status.
Read those numbers together and a pattern jumps out: the funnel is wide at the top and brutally narrow further down. Plenty of founders are getting a first check. Very few are getting a fourth or fifth. The distance between seed and Series A isn't a gap, it's a chasm, and it's the single biggest bottleneck standing between "864% growth in company count" and "864% growth in companies that matter at scale." Geographically, it's mostly a London story, though Bristol's Micrima shows the sector isn't purely a capital-city phenomenon.
Investment trends over the past decade: the trajectory and what the 2024 peak reveals
Here's where the numbers get genuinely dramatic. UK FemTech investment went from £11.7 million in 2020 to £177.1 million in 2024, according to Beauhurst, more than a fifteen-fold jump in four years. If you'd told a founder in 2020 that four years later the sector would be raising fifteen times as much annually, they'd have laughed you out of the pitch meeting.
2025 came down from that peak, landing at £77.2 million for the full year, still the second-highest annual total on record. A step down from 2024, sure, but not a collapse; call it a correction after an unusually good year, not a warning sign.
Zoom out to a decade and the trend lines are even clearer. Mills & Reeve's July 2025 analysis found deal count up more than 194% between 2015 and 2025, and the number of VC deals specifically up 600% over the same window. Average deal size more than tripled, from £527,000 in 2015 to £1.9 million in 2025. Cumulative equity funding across UK FemTech companies now stands at £477.6 million in Beauhurst's dataset, and 87% of that total was raised since 2020. Say that last part again slowly: nearly nine in every ten pounds this sector has ever raised came in the last five years. This isn't a mature industry with a long funding history. It's a young industry that suddenly found its footing.
The biggest 2025 rounds tell a similar story of domestic confidence: SheMed raised more than £37 million, Gaia brought in £12 million, emm raised £6.8 million, and Hertility closed £5.9 million. Most of the investors behind these rounds were UK-based, which matters, because it means British capital believes in British FemTech rather than waiting for American VCs to validate the thesis first.
And exits are starting to show up too. The clearest one: Hologic's acquisition of Endomagnetics for roughly $310 million in 2024, a UCL spin-out that proved a UK diagnostics company could become an attractive target for a major strategic acquirer. One data point doesn't make a trend, but it's the kind of data point the whole sector points to when someone asks "but can you actually exit in this space?"
The companies that have defined the ecosystem: Flo, Elvie, and what they prove
Every young industry needs a proof-of-concept company, the one that makes skeptical investors stop asking "but is there really a market here?" For UK FemTech, that's Flo Health.
Flo is a London-headquartered period and fertility tracking app that raised more than $200 million in a Series C from General Atlantic in July 2024, pushing its valuation above $1 billion and making it the first purely digital, consumer-facing women's health app to reach unicorn status. As of June 2024 it had close to 70 million monthly active users and nearly 5 million paying subscribers, numbers that would make most consumer app founders weep with envy. It's raised $269 million in total funding as of May 2026, per Tracxn, more than any other UK FemTech company. Revenue jumped sharply between 2022 and 2023, and gross bookings for 2024 were expected to top $200 million, roughly a 50% year-over-year climb at the time of the raise. What Flo proves, in one sentence: a freemium, data-heavy consumer product built around reproductive health can scale globally from a British base without needing to relocate to San Francisco to do it.
Then there's Elvie, the hardware side of the same coin. Best known for its silent wearable breast pump and its smart pelvic floor trainer, Elvie showed the market that FemTech hardware, not just apps, could be well-designed, clinically credible, and genuinely profitable. Before Flo's 2024 raise, Elvie's Series C was the largest single funding round any UK FemTech startup had pulled off, and it remains the benchmark for what a hardware exit in this space looks like. What Elvie proves is almost the mirror image of Flo's lesson: physical products designed specifically for women's bodies were, and still are, an underserved category, and buyers will pay a premium for something that's actually built with them in mind rather than shrunk down from a men's product.
Worth mentioning too: Peppy, which delivers fertility and menopause support through employer benefit packages rather than direct-to-consumer sales. It's raised £46.4 million, per Beauhurst, and represents a completely different go-to-market playbook, selling through HR departments instead of app stores. And a newer wave, including SheMed, Micrima, and Hertility, is pushing into weight management, breast diagnostics, and at-home hormone testing, proving the sector is broadening well past its period-tracking roots. The thread connecting all of them: each one solved a specific, clinically grounded problem rather than trying to build a do-everything women's wellness platform. That focus seems to be exactly what separates the companies that raise Series C from the 43.8% still waiting on their first check.
The four sectors drawing the most attention: fertility, menopause, menstrual health, and diagnostics
Fertility and reproductive health takes the biggest slice of the pie once you combine reproductive health, contraception, and pregnancy and nursing. Two distinct product models compete for the same demand here: at-home testing kits from companies like Hertility and Natural Cycles, and app-based tracking from Flo. Worth watching is the regulatory pressure building around fertility data privacy; any company whose whole business model runs on intimate health data is going to face more scrutiny as data protection rules catch up with what these apps actually collect.
Menopause is the category that makes you tilt your head. Just 6% of sub-sector market share, despite being one of the loudest topics in British public life since around 2022, when NHS policy attention and media coverage genuinely surged. Peppy's employer-benefits model is trying to close that gap by treating menopause support as a workplace issue rather than a personal medical one, which is a smart bet given how many British employers are now under pressure to do something, anything, about it. This is a rare case where institutional and cultural demand is running ahead of the products available to meet it.
Menstrual health holds 14% market share and is, in a real sense, where this whole industry started. Most of the earliest FemTech companies were period trackers. The app layer here is fairly mature now, so the interesting competition has moved toward diagnostics and condition-specific tools, things built for endometriosis or PCOS rather than general cycle tracking.
Diagnostics is its own animal entirely. Micrima's breast-scanning technology and Endomagnetics (now part of Hologic) point to a medical-device track that runs on a completely different clock than the consumer app world. Endomagnetics started as a UCL spin-out, which says something important: university tech transfer is a real and repeatable pipeline for diagnostic FemTech, not a one-off fluke. The regulatory bar is higher here, MHRA and CE marking take time and money that a consumer app never has to spend, but the exit multiples can be higher too. Hologic paying roughly $310 million for Endomagnetics is the ceiling everyone in this sub-sector points to.
Threading through all four categories is one uncomfortable gap: mental health sits at just 2% of market share, despite plenty of evidence that women's mental health is underserved almost everywhere. That's a category where the money simply hasn't followed the need yet.
The structural factors enabling UK FemTech growth
Why the UK specifically? A few things line up here that don't line up the same way in most other countries.
The NHS functions as both a testing ground and a credibility stamp. UK startups can point to NHS data infrastructure and existing clinical relationships as validation, and even though NHS procurement moves at the speed of continental drift, getting anywhere near it signals legitimacy to investors and to international buyers eyeing UK health tech for expansion. Layer on top of that the government's renewed Women's Health Strategy, referenced repeatedly in parliamentary evidence sessions, which tells investors that regulatory and procurement risk in this category is trending downward rather than up.
Universities matter more than people realize. UCL, Bristol, and other research institutions are feeding diagnostics and device startups into the pipeline, and Endomagnetics is the cleanest example of academic research turning into a $310 million acquisition. London's dual identity as both a life sciences hub and a consumer tech hub means FemTech gets to sit at the intersection of two ecosystems that were already well-funded before FemTech had a name.
The investor base itself is maturing too. Most of the money behind 2025's largest rounds came from UK-based investors, which means the country is now generating its own domestic capital for this sector rather than depending entirely on American or European VCs to write the big checks. And a new revenue channel has opened up through corporate benefits: Peppy and Matresa are selling fertility and menopause support through employers, which is a much cheaper way to acquire users than fighting for consumer attention app by app, and it comes with the kind of recurring revenue that makes finance teams sleep better at night.
Finally, the sector is starting to organize itself politically. Femtech Assembly and similar advocacy groups are formalizing the industry's voice in policy discussions, and the fact that Ida Tin, the person who coined the term in the first place, now runs a dedicated think tank on the subject tells you this sector has moved past the scrappy-startup phase into something that wants a seat at the regulatory table.
The funding gaps and structural challenges the ecosystem has not yet solved
For all that growth, the same structural problems keep showing up, and they're worth naming plainly rather than glossing over in the excitement of a fifteen-fold funding increase.
The pre-seed to Series A gap is the big one. With 43.8% of companies never having raised outside money and only 25 total reaching Series A or later, the funnel narrows sharply right after seed, which is exactly the stage where a company needs capital to run clinical validation or start the regulatory process. An average deal size of £1.9 million in 2025, while triple what it was a decade ago, is still modest next to typical medtech or digital health benchmarks elsewhere. UK FemTech is raising at volume, plenty of small and mid-size checks, but not yet at the size that lets a hardware or diagnostics company clear MHRA approval without running out of runway first.
There's also a persistent mismatch between who builds this sector and who funds it. FemTech is overwhelmingly women-led and built for women's health outcomes, yet mainstream VC remains dominated by male partners, and female founders consistently report the same conversation on repeat: investors questioning market size for products addressing health issues that affect roughly half the population. It's an odd kind of skepticism when you say it out loud, and yet it keeps happening.
And regulation creates a genuine two-speed problem. Consumer apps like Flo can iterate fast and ship updates whenever they want. Devices and diagnostics, Micrima and the Endomagnetics-style companies, have to clear MHRA and CE marking requirements that take years, not sprints. Both tracks have strong clinical merit; only one of them moves at startup speed. Until financing catches up with that reality, and starts writing checks sized for the years-long regulatory slog rather than the app-store update cycle, the UK FemTech ecosystem will keep doing what it's done for the past decade: producing a wide and enthusiastic front end, and a narrow, hard-won path to actually scaling.
